Mr. Robert (Bob) E. Ward, Chairman of the Board and Chief Executive Officer of Eloxx Pharmaceuticals provides an overview of his company’s leading drug candidate, ELX-02 for cystic fibrosis.

ELX-02 is designed to increase the read-through activity in patients with nonsense mutations and enable the production of sufficient amounts of full-length protein to restore activity of the mutated protein. ELX-02 is focused on development for cystic fibrosis and cystinosis patients with diagnosed nonsense mutations on one or both alleles represents a high unmet medical need as there are currently no approved therapeutics targeting the impairment caused by these mutations.